GB1429184A
(en)
|
1972-04-20 |
1976-03-24 |
Allen & Hanburys Ltd |
Physically anti-inflammatory steroids for use in aerosols
|
US4044126A
(en)
|
1972-04-20 |
1977-08-23 |
Allen & Hanburys Limited |
Steroidal aerosol compositions and process for the preparation thereof
|
US4444887A
(en)
|
1979-12-10 |
1984-04-24 |
Sloan-Kettering Institute |
Process for making human antibody producing B-lymphocytes
|
US4716111A
(en)
|
1982-08-11 |
1987-12-29 |
Trustees Of Boston University |
Process for producing human antibodies
|
GB8308235D0
(en)
|
1983-03-25 |
1983-05-05 |
Celltech Ltd |
Polypeptides
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
US5807715A
(en)
|
1984-08-27 |
1998-09-15 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
|
WO1986005807A1
(en)
|
1985-04-01 |
1986-10-09 |
Celltech Limited |
Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
|
GB8601597D0
(en)
|
1986-01-23 |
1986-02-26 |
Wilson R H |
Nucleotide sequences
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
GB8607679D0
(en)
|
1986-03-27 |
1986-04-30 |
Winter G P |
Recombinant dna product
|
US5869620A
(en)
|
1986-09-02 |
1999-02-09 |
Enzon, Inc. |
Multivalent antigen-binding proteins
|
EP0307434B2
(en)
|
1987-03-18 |
1998-07-29 |
Scotgen Biopharmaceuticals, Inc. |
Altered antibodies
|
GB8717430D0
(en)
|
1987-07-23 |
1987-08-26 |
Celltech Ltd |
Recombinant dna product
|
US5677425A
(en)
|
1987-09-04 |
1997-10-14 |
Celltech Therapeutics Limited |
Recombinant antibody
|
DE768377T1
(en)
|
1988-09-02 |
1998-01-02 |
Dyax Corp |
Production and selection of recombinant proteins with different binding sites
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
US5413923A
(en)
|
1989-07-25 |
1995-05-09 |
Cell Genesys, Inc. |
Homologous recombination for universal donor cells and chimeric mammalian hosts
|
GB8928874D0
(en)
|
1989-12-21 |
1990-02-28 |
Celltech Ltd |
Humanised antibodies
|
US5585112A
(en)
|
1989-12-22 |
1996-12-17 |
Imarx Pharmaceutical Corp. |
Method of preparing gas and gaseous precursor-filled microspheres
|
AU7247191A
(en)
|
1990-01-11 |
1991-08-05 |
Molecular Affinities Corporation |
Production of antibodies using gene libraries
|
US5780225A
(en)
|
1990-01-12 |
1998-07-14 |
Stratagene |
Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
|
DE69120146T2
(en)
|
1990-01-12 |
1996-12-12 |
Cell Genesys Inc |
GENERATION OF XENOGENIC ANTIBODIES
|
US6075181A
(en)
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
IT1246382B
(en)
|
1990-04-17 |
1994-11-18 |
Eurand Int |
METHOD FOR THE TARGETED AND CONTROLLED DELIVERY OF DRUGS IN THE INTESTINE AND PARTICULARLY IN THE COLON
|
US5427908A
(en)
|
1990-05-01 |
1995-06-27 |
Affymax Technologies N.V. |
Recombinant library screening methods
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
US5633425A
(en)
|
1990-08-29 |
1997-05-27 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
US5625126A
(en)
|
1990-08-29 |
1997-04-29 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
US5661016A
(en)
|
1990-08-29 |
1997-08-26 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
ES2246502T3
(en)
|
1990-08-29 |
2006-02-16 |
Genpharm International, Inc. |
TRANSGENIC NON-HUMAN ANIMALS ABLE TO PRODUCE HETEROLOGICAL ANTIBODIES.
|
US5814318A
(en)
|
1990-08-29 |
1998-09-29 |
Genpharm International Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
US5698426A
(en)
|
1990-09-28 |
1997-12-16 |
Ixsys, Incorporated |
Surface expression libraries of heteromeric receptors
|
US5543390A
(en)
|
1990-11-01 |
1996-08-06 |
State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University |
Covalent microparticle-drug conjugates for biological targeting
|
ES2113940T3
(en)
|
1990-12-03 |
1998-05-16 |
Genentech Inc |
ENRICHMENT METHOD FOR PROTEIN VARIANTS WITH ALTERED UNION PROPERTIES.
|
DE69233750D1
(en)
|
1991-04-10 |
2009-01-02 |
Scripps Research Inst |
Libraries of heterodimeric receptors using phagemids
|
EP0519596B1
(en)
|
1991-05-17 |
2005-02-23 |
Merck & Co. Inc. |
A method for reducing the immunogenicity of antibody variable domains
|
AU2238292A
(en)
|
1991-06-14 |
1993-01-12 |
Xoma Corporation |
Microbially-produced antibody fragments and their conjugates
|
ES2206447T3
(en)
|
1991-06-14 |
2004-05-16 |
Genentech, Inc. |
HUMANIZED ANTIBODY FOR HEREGULINE.
|
US5637481A
(en)
|
1993-02-01 |
1997-06-10 |
Bristol-Myers Squibb Company |
Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
|
ES2136092T3
(en)
|
1991-09-23 |
1999-11-16 |
Medical Res Council |
PROCEDURES FOR THE PRODUCTION OF HUMANIZED ANTIBODIES.
|
DK1024191T3
(en)
|
1991-12-02 |
2008-12-08 |
Medical Res Council |
Preparation of autoantibodies displayed on phage surfaces from antibody segment libraries
|
ES2202310T3
(en)
|
1991-12-13 |
2004-04-01 |
Xoma Corporation |
METHODS AND MATERIALS FOR THE PREPARATION OF VARIABLE DOMAINS OF MODIFIED ANTIBODIES AND THEIR THERAPEUTIC USES.
|
GB9203459D0
(en)
|
1992-02-19 |
1992-04-08 |
Scotgen Ltd |
Antibodies with germ-line variable regions
|
US5733743A
(en)
|
1992-03-24 |
1998-03-31 |
Cambridge Antibody Technology Limited |
Methods for producing members of specific binding pairs
|
GB9206422D0
(en)
|
1992-03-24 |
1992-05-06 |
Bolt Sarah L |
Antibody preparation
|
US6174666B1
(en)
|
1992-03-27 |
2001-01-16 |
The United States Of America As Represented By The Department Of Health And Human Services |
Method of eliminating inhibitory/instability regions from mRNA
|
US6010715A
(en)
|
1992-04-01 |
2000-01-04 |
Bertek, Inc. |
Transdermal patch incorporating a polymer film incorporated with an active agent
|
US6024975A
(en)
|
1992-04-08 |
2000-02-15 |
Americare International Diagnostics, Inc. |
Method of transdermally administering high molecular weight drugs with a polymer skin enhancer
|
WO1993022332A2
(en)
|
1992-04-24 |
1993-11-11 |
Board Of Regents, The University Of Texas System |
Recombinant production of immunoglobulin-like domains in prokaryotic cells
|
ES2162823T5
(en)
|
1992-08-21 |
2010-08-09 |
Vrije Universiteit Brussel |
IMMUNOGLOBULINS DESPROVISTAS OF LIGHT CHAINS.
|
US6005079A
(en)
|
1992-08-21 |
1999-12-21 |
Vrije Universiteit Brussels |
Immunoglobulins devoid of light chains
|
US5639641A
(en)
|
1992-09-09 |
1997-06-17 |
Immunogen Inc. |
Resurfacing of rodent antibodies
|
JP3720353B2
(en)
|
1992-12-04 |
2005-11-24 |
メディカル リサーチ カウンシル |
Multivalent and multispecific binding proteins, their production and use
|
US6274552B1
(en)
|
1993-03-18 |
2001-08-14 |
Cytimmune Sciences, Inc. |
Composition and method for delivery of biologically-active factors
|
US5523092A
(en)
|
1993-04-14 |
1996-06-04 |
Emory University |
Device for local drug delivery and methods for using the same
|
US5985307A
(en)
|
1993-04-14 |
1999-11-16 |
Emory University |
Device and method for non-occlusive localized drug delivery
|
AU6796094A
(en)
|
1993-04-29 |
1994-11-21 |
Raymond Hamers |
Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of (camelidae)
|
JPH08511420A
(en)
|
1993-06-16 |
1996-12-03 |
セルテック・セラピューテイクス・リミテッド |
Body
|
US6004534A
(en)
|
1993-07-23 |
1999-12-21 |
Massachusetts Institute Of Technology |
Targeted polymerized liposomes for improved drug delivery
|
EP0733070A1
(en)
|
1993-12-08 |
1996-09-25 |
Genzyme Corporation |
Process for generating specific antibodies
|
GB9326253D0
(en)
|
1993-12-23 |
1994-02-23 |
Smithkline Beecham Biolog |
Vaccines
|
US5997873A
(en)
|
1994-01-13 |
1999-12-07 |
Mount Sinai School Of Medicine Of The City University Of New York |
Method of preparation of heat shock protein 70-peptide complexes
|
IL108501A
(en)
|
1994-01-31 |
1998-10-30 |
Mor Research Applic Ltd |
Antibodies and pharmaceutical compositions containing them
|
DK0744958T3
(en)
|
1994-01-31 |
2003-10-20 |
Univ Boston |
Polyclonal antibody libraries
|
US5516637A
(en)
|
1994-06-10 |
1996-05-14 |
Dade International Inc. |
Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
|
US5759542A
(en)
|
1994-08-05 |
1998-06-02 |
New England Deaconess Hospital Corporation |
Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
|
US5660854A
(en)
|
1994-11-28 |
1997-08-26 |
Haynes; Duncan H |
Drug releasing surgical implant or dressing material
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
US6121022A
(en)
|
1995-04-14 |
2000-09-19 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
US5983134A
(en)
|
1995-04-23 |
1999-11-09 |
Electromagnetic Bracing Systems Inc. |
Electrophoretic cuff apparatus drug delivery system
|
ES2304786T3
(en)
|
1995-04-27 |
2008-10-16 |
Amgen Fremont Inc. |
ANTI-IL-8 HUMAN ANTIBODIES, DERIVED FROM IMMUNIZED XENORATONES.
|
EP0823941A4
(en)
|
1995-04-28 |
2001-09-19 |
Abgenix Inc |
Human antibodies derived from immunized xenomice
|
US6316652B1
(en)
|
1995-06-06 |
2001-11-13 |
Kosta Steliou |
Drug mitochondrial targeting agents
|
US6167301A
(en)
|
1995-08-29 |
2000-12-26 |
Flower; Ronald J. |
Iontophoretic drug delivery device having high-efficiency DC-to-DC energy conversion circuit
|
US5935576A
(en)
|
1995-09-13 |
1999-08-10 |
Fordham University |
Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
|
GB9601081D0
(en)
|
1995-10-06 |
1996-03-20 |
Cambridge Antibody Tech |
Specific binding members for human transforming growth factor beta;materials and methods
|
WO1997014719A1
(en)
|
1995-10-16 |
1997-04-24 |
Unilever N.V. |
A bifunctional or bivalent antibody fragment analogue
|
US6039975A
(en)
|
1995-10-17 |
2000-03-21 |
Hoffman-La Roche Inc. |
Colon targeted delivery system
|
JP2978435B2
(en)
|
1996-01-24 |
1999-11-15 |
チッソ株式会社 |
Method for producing acryloxypropyl silane
|
DE69731289D1
(en)
|
1996-03-18 |
2004-11-25 |
Univ Texas |
IMMUNGLOBULIN-LIKE DOMAIN WITH INCREASED HALF-VALUE TIMES
|
TW345603B
(en)
|
1996-05-29 |
1998-11-21 |
Gmundner Fertigteile Gmbh |
A noise control device for tracks
|
US6027947A
(en)
|
1996-08-20 |
2000-02-22 |
Ramtron International Corporation |
Partially or completely encapsulated top electrode of a ferroelectric capacitor
|
US5985317A
(en)
|
1996-09-06 |
1999-11-16 |
Theratech, Inc. |
Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents
|
EP1007012A4
(en)
|
1996-10-01 |
2006-01-18 |
Cima Labs Inc |
Taste-masked microcapsule compositions and methods of manufacture
|
US5916771A
(en)
|
1996-10-11 |
1999-06-29 |
Abgenix, Inc. |
Production of a multimeric protein by cell fusion method
|
US6131570A
(en)
|
1998-06-30 |
2000-10-17 |
Aradigm Corporation |
Temperature controlling device for aerosol drug delivery
|
WO1998023289A1
(en)
|
1996-11-27 |
1998-06-04 |
The General Hospital Corporation |
MODULATION OF IgG BINDING TO FcRn
|
DK1500329T3
(en)
|
1996-12-03 |
2012-07-09 |
Amgen Fremont Inc |
Human antibodies that specifically bind TNF-alpha
|
US6017540A
(en)
|
1997-02-07 |
2000-01-25 |
Fordham University |
Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes
|
US5860957A
(en)
|
1997-02-07 |
1999-01-19 |
Sarcos, Inc. |
Multipathway electronically-controlled drug delivery system
|
US6277375B1
(en)
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
US6120751A
(en)
|
1997-03-21 |
2000-09-19 |
Imarx Pharmaceutical Corp. |
Charged lipids and uses for the same
|
WO1998046645A2
(en)
|
1997-04-14 |
1998-10-22 |
Micromet Gesellschaft Für Biomedizinische Forschung Mbh |
Method for the production of antihuman antigen receptors and uses thereof
|
US6060082A
(en)
|
1997-04-18 |
2000-05-09 |
Massachusetts Institute Of Technology |
Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
|
US20020062010A1
(en)
|
1997-05-02 |
2002-05-23 |
Genentech, Inc. |
Method for making multispecific antibodies having heteromultimeric and common components
|
US7951917B1
(en)
|
1997-05-02 |
2011-05-31 |
Genentech, Inc. |
Method for making multispecific antibodies having heteromultimeric and common components
|
US6235883B1
(en)
|
1997-05-05 |
2001-05-22 |
Abgenix, Inc. |
Human monoclonal antibodies to epidermal growth factor receptor
|
US5948433A
(en)
|
1997-08-21 |
1999-09-07 |
Bertek, Inc. |
Transdermal patch
|
AU734180B2
(en)
|
1997-08-29 |
2001-06-07 |
Antigenics Llc |
Compositions comprising the adjuvant qs-21 and polysorbate or cyclodextrin as excipient
|
CA2275539A1
(en)
|
1997-10-28 |
1999-05-06 |
Bando Chemical Industries, Ltd. |
A transdermal patch and a method for manufacture of a substrate sheet therefor
|
US5948646A
(en)
|
1997-12-11 |
1999-09-07 |
Fordham University |
Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
US6048736A
(en)
|
1998-04-29 |
2000-04-11 |
Kosak; Kenneth M. |
Cyclodextrin polymers for carrying and releasing drugs
|
JP4620251B2
(en)
|
1998-08-10 |
2011-01-26 |
アンチジェニックス・インコーポレイテッド |
Composition of CPG and saponin adjuvant and method thereof
|
US7109003B2
(en)
|
1998-12-23 |
2006-09-19 |
Abgenix, Inc. |
Methods for expressing and recovering human monoclonal antibodies to CTLA-4
|
HUP0104865A3
(en)
|
1999-01-15 |
2004-07-28 |
Genentech Inc |
Polypeptide variants with altered effector function
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
IL129299A0
(en)
|
1999-03-31 |
2000-02-17 |
Mor Research Applic Ltd |
Monoclonal antibodies antigens and diagnosis of malignant diseases
|
US6271359B1
(en)
|
1999-04-14 |
2001-08-07 |
Musc Foundation For Research Development |
Tissue-specific and pathogen-specific toxic agents and ribozymes
|
US6256533B1
(en)
|
1999-06-09 |
2001-07-03 |
The Procter & Gamble Company |
Apparatus and method for using an intracutaneous microneedle array
|
US6808710B1
(en)
|
1999-08-23 |
2004-10-26 |
Genetics Institute, Inc. |
Downmodulating an immune response with multivalent antibodies to PD-1
|
EP2829609A1
(en)
|
1999-08-24 |
2015-01-28 |
E. R. Squibb & Sons, L.L.C. |
Human CTLA-4 antibodies and their uses
|
US7605238B2
(en)
|
1999-08-24 |
2009-10-20 |
Medarex, Inc. |
Human CTLA-4 antibodies and their uses
|
AU2161501A
(en)
|
1999-11-29 |
2001-06-25 |
Unilever Plc |
Immobilized single domain antigen-binding molecules
|
AU2001233027A1
(en)
|
2000-01-27 |
2001-08-07 |
Genetics Institute, Llc |
Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof
|
EP1125905A1
(en)
|
2000-02-16 |
2001-08-22 |
Pepscan Systems B.V. |
Segment synthesis
|
US6261595B1
(en)
|
2000-02-29 |
2001-07-17 |
Zars, Inc. |
Transdermal drug patch with attached pocket for controlled heating device
|
PT2275449T
(en)
*
|
2000-06-16 |
2016-12-27 |
Human Genome Sciences Inc |
Antibodies that immunospecifically bind to blys
|
EP1197755A1
(en)
|
2000-10-11 |
2002-04-17 |
Pepscan Systems B.V. |
Identification of protein binding sites
|
US7658921B2
(en)
|
2000-12-12 |
2010-02-09 |
Medimmune, Llc |
Molecules with extended half-lives, compositions and uses thereof
|
EP2341060B1
(en)
|
2000-12-12 |
2019-02-20 |
MedImmune, LLC |
Molecules with extended half-lives, compositions and uses thereof
|
WO2002066984A2
(en)
|
2001-02-16 |
2002-08-29 |
Pepscan Systems B.V. |
Arrays for determining binding of biomolecules
|
AR036993A1
(en)
|
2001-04-02 |
2004-10-20 |
Wyeth Corp |
USE OF AGENTS THAT MODULATE THE INTERACTION BETWEEN PD-1 AND ITS LINKS IN THE SUBMODULATION OF IMMUNOLOGICAL ANSWERS
|
WO2004006955A1
(en)
|
2001-07-12 |
2004-01-22 |
Jefferson Foote |
Super humanized antibodies
|
ATE524495T1
(en)
|
2001-07-31 |
2011-09-15 |
Ono Pharmaceutical Co |
PD-1 SPECIFIC SUBSTANCE
|
US20040014194A1
(en)
|
2002-03-27 |
2004-01-22 |
Schering Corporation |
Beta-secretase crystals and methods for preparing and using the same
|
IL149820A0
(en)
|
2002-05-23 |
2002-11-10 |
Curetech Ltd |
Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
|
FI2206517T3
(en)
|
2002-07-03 |
2023-10-19 |
Ono Pharmaceutical Co |
Immunopotentiating compositions comprising anti-PD-L1 antibodies
|
JP4511943B2
(en)
|
2002-12-23 |
2010-07-28 |
ワイス エルエルシー |
Antibody against PD-1 and use thereof
|
US9068234B2
(en)
|
2003-01-21 |
2015-06-30 |
Ptc Therapeutics, Inc. |
Methods and agents for screening for compounds capable of modulating gene expression
|
ES2729974T3
(en)
|
2003-01-23 |
2019-11-07 |
Ono Pharmaceutical Co |
Specific antibody of human PD-1 and CD3
|
EP1660534A2
(en)
|
2003-08-22 |
2006-05-31 |
MedImmune, Inc. |
Humanization of antibodies
|
US7288638B2
(en)
|
2003-10-10 |
2007-10-30 |
Bristol-Myers Squibb Company |
Fully human antibodies against human 4-1BB
|
GB0400440D0
(en)
|
2004-01-09 |
2004-02-11 |
Isis Innovation |
Receptor modulators
|
US20090304679A1
(en)
|
2004-05-27 |
2009-12-10 |
Weidanz Jon A |
Antibodies as T cell receptor mimics, methods of production and uses thereof
|
MX2007004176A
(en)
|
2004-10-06 |
2007-06-15 |
Mayo Foundation |
B7-h1 and methods of diagnosis, prognosis, and treatment of cancer.
|
AU2005319382B2
(en)
*
|
2004-12-21 |
2011-04-07 |
Astrazeneca Ab |
Antibodies directed to angiopoietin-2 and uses thereof
|
DE102004063494A1
(en)
|
2004-12-23 |
2006-07-13 |
Tegenero Ag |
antibody
|
US20060240006A1
(en)
|
2005-04-20 |
2006-10-26 |
Chishih Chu |
Novel antibody structures derived from human germline sequences
|
LT2439273T
(en)
*
|
2005-05-09 |
2019-05-10 |
Ono Pharmaceutical Co., Ltd. |
Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
|
RU2596491C2
(en)
|
2005-06-08 |
2016-09-10 |
Дана-Фарбер Кэнсер Инститьют |
Methods and compositions for treating persistent infections
|
TW200813091A
(en)
*
|
2006-04-10 |
2008-03-16 |
Amgen Fremont Inc |
Targeted binding agents directed to uPAR and uses thereof
|
AU2007331672A1
(en)
|
2006-12-15 |
2008-06-19 |
Ablynx N.V. |
Amino acid sequences that modulate the interaction between cells of the immune system
|
CN101663323A
(en)
|
2006-12-27 |
2010-03-03 |
埃默里大学 |
The composition and the method that are used for the treatment of transmissible disease and tumour
|
DK2170959T3
(en)
*
|
2007-06-18 |
2014-01-13 |
Merck Sharp & Dohme |
ANTIBODIES AGAINST HUMAN PROGRAMMED DEATH RECEPTOR PD-1
|
ES2591281T3
(en)
|
2007-07-12 |
2016-11-25 |
Gitr, Inc. |
Combination therapies that employ GITR binding molecules
|
US9243052B2
(en)
|
2007-08-17 |
2016-01-26 |
Daniel Olive |
Method for treating and diagnosing hematologic malignancies
|
CL2008002444A1
(en)
*
|
2007-08-21 |
2009-09-04 |
Amgen Inc |
Antibody or fragment thereof that binds to human c-fms protein; nucleic acid molecule that encodes it; vector and host cell; production method; pharmaceutical composition comprising it; and its use to treat or prevent a condition associated with c-fms in a patient.
|
US20090304719A1
(en)
|
2007-08-22 |
2009-12-10 |
Patrick Daugherty |
Activatable binding polypeptides and methods of identification and use thereof
|
MX2010003380A
(en)
*
|
2007-09-26 |
2010-10-15 |
U3 Pharma Gmbh |
Heparin-binding epidermal growth factor-like growth factor antigen binding proteins.
|
US8227577B2
(en)
|
2007-12-21 |
2012-07-24 |
Hoffman-La Roche Inc. |
Bivalent, bispecific antibodies
|
EP2262837A4
(en)
|
2008-03-12 |
2011-04-06 |
Merck Sharp & Dohme |
Pd-1 binding proteins
|
SG10201402815VA
(en)
|
2008-04-09 |
2014-09-26 |
Genentech Inc |
Novel compositions and methods for the treatment of immune related diseases
|
KR20110044992A
(en)
*
|
2008-07-02 |
2011-05-03 |
이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 |
TVF-β antagonist multi-target binding protein
|
KR101783004B1
(en)
|
2008-07-08 |
2017-09-28 |
인사이트 홀딩스 코포레이션 |
1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
|
AR072999A1
(en)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE
|
AU2009290544B2
(en)
|
2008-09-12 |
2015-07-16 |
Oxford University Innovation Limited |
PD-1 specific antibodies and uses thereof
|
WO2010029434A1
(en)
|
2008-09-12 |
2010-03-18 |
Isis Innovation Limited |
Pd-1 specific antibodies and uses thereof
|
ES2592216T3
(en)
|
2008-09-26 |
2016-11-28 |
Dana-Farber Cancer Institute, Inc. |
Human anti-PD-1, PD-L1 and PD-L2 antibodies and their uses
|
KR101050829B1
(en)
|
2008-10-02 |
2011-07-20 |
서울대학교산학협력단 |
Anticancer agents comprising an anti-PD-1 antibody or an anti-PD-L1 antibody
|
JP5844159B2
(en)
|
2009-02-09 |
2016-01-13 |
ユニヴェルシテ デクス−マルセイユUniversite D’Aix−Marseille |
PD-1 antibody and PD-L1 antibody and use thereof
|
GB0903325D0
(en)
|
2009-02-26 |
2009-04-08 |
Univ Aberdeen |
Antibody molecules
|
WO2010102278A1
(en)
|
2009-03-06 |
2010-09-10 |
President And Fellows Of Harvard College |
Methods and compositions for the generation and maintenance of regulatory t cells
|
WO2010108153A2
(en)
*
|
2009-03-20 |
2010-09-23 |
Amgen Inc. |
Carrier immunoglobulins and uses thereof
|
AU2010265933B2
(en)
|
2009-06-26 |
2015-05-14 |
Regeneron Pharmaceuticals, Inc. |
Readily isolated bispecific antibodies with native immunoglobulin format
|
JP5920929B2
(en)
|
2010-03-11 |
2016-05-18 |
ユセベ ファルマ ソシエテ アノニム |
PD-1 antibody
|
TW201134488A
(en)
|
2010-03-11 |
2011-10-16 |
Ucb Pharma Sa |
PD-1 antibodies
|
JP2013532153A
(en)
|
2010-06-18 |
2013-08-15 |
ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド |
Bispecific antibodies against TIM-3 and PD-1 for immunotherapy against chronic immune disease
|
NZ629913A
(en)
|
2010-08-23 |
2016-01-29 |
Univ Texas |
Anti-ox40 antibodies and methods of using the same
|
GB201103955D0
(en)
|
2011-03-09 |
2011-04-20 |
Antitope Ltd |
Antibodies
|
US9555108B2
(en)
|
2011-03-24 |
2017-01-31 |
Texas Tech University System |
TCR mimic antibodies as vascular targeting tools
|
CN103429264A
(en)
|
2011-03-31 |
2013-12-04 |
默沙东公司 |
Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments
|
PE20141271A1
(en)
|
2011-04-01 |
2014-10-08 |
Sloan Kettering Inst Cancer |
T-CELL RECEPTOR TYPE ANTIBODIES SPECIFIC TO A WT1 PEPTIDE PRESENTED BY HLA-A2
|
LT2699264T
(en)
|
2011-04-20 |
2018-07-10 |
Medimmune, Llc |
Antibodies and other molecules that bind b7-h1 and pd-1
|
CA2840170A1
(en)
|
2011-06-21 |
2012-12-27 |
The Johns Hopkins University |
Focused radiation for augmenting immune-based therapies against neoplasms
|
ES2893855T3
(en)
|
2011-08-11 |
2022-02-10 |
Ono Pharmaceutical Co |
Therapeutic agent for autoimmune diseases comprising PD-1 agonist
|
US9856320B2
(en)
|
2012-05-15 |
2018-01-02 |
Bristol-Myers Squibb Company |
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
|
WO2014039983A1
(en)
|
2012-09-07 |
2014-03-13 |
The Trustees Of Dartmouth College |
Vista modulators for diagnosis and treatment of cancer
|
US11180572B2
(en)
|
2012-07-06 |
2021-11-23 |
Genmab B.V. |
Dimeric protein with triple mutations
|
EP2906241B1
(en)
|
2012-10-12 |
2020-01-08 |
The Brigham and Women's Hospital, Inc. |
Enhancement of the immune response
|
WO2014066834A1
(en)
|
2012-10-26 |
2014-05-01 |
The University Of Chicago |
Synergistic combination of immunologic inhibitors for the treatment of cancer
|
SG10201704611WA
(en)
|
2012-12-13 |
2017-07-28 |
Aduro Biotech Inc |
Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
|
ES2721168T3
(en)
|
2013-01-11 |
2019-07-29 |
Dingfu Biotarget Co Ltd |
Agents to treat tumors, use and method thereof
|
CN109045289A
(en)
|
2013-02-22 |
2018-12-21 |
库瑞瓦格股份公司 |
Vaccine inoculation and the combination for inhibiting PD-1 approach
|
EP2958588B1
(en)
|
2013-02-22 |
2017-08-23 |
CureVac AG |
Combination of vaccination and inhibition of the pd-1 pathway
|
EP2968985A2
(en)
*
|
2013-03-15 |
2016-01-20 |
Amgen, Inc. |
Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9
|
WO2014161509A1
(en)
|
2013-04-05 |
2014-10-09 |
The University Of Hong Kong |
Novel pd1 isoforms, and uses thereof for potentiating immune responses
|
RS61400B1
(en)
*
|
2013-05-02 |
2021-02-26 |
Anaptysbio Inc |
Antibodies directed against programmed death-1 (pd-1)
|
CN105683217B
(en)
*
|
2013-05-31 |
2019-12-10 |
索伦托治疗有限公司 |
Antigen binding proteins that bind to PD-1
|
WO2014209804A1
(en)
|
2013-06-24 |
2014-12-31 |
Biomed Valley Discoveries, Inc. |
Bispecific antibodies
|
CN104250302B
(en)
|
2013-06-26 |
2017-11-14 |
上海君实生物医药科技股份有限公司 |
The anti-antibody of PD 1 and its application
|
GB201311487D0
(en)
|
2013-06-27 |
2013-08-14 |
Alligator Bioscience Ab |
Bispecific molecules
|
KR20160030936A
(en)
|
2013-07-16 |
2016-03-21 |
제넨테크, 인크. |
Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors
|
AR097306A1
(en)
|
2013-08-20 |
2016-03-02 |
Merck Sharp & Dohme |
MODULATION OF TUMOR IMMUNITY
|
EP3036258B1
(en)
|
2013-08-22 |
2023-07-19 |
The Council of the Queensland Institute of Medical Research |
Immunoreceptor modulation for treating cancer and viral infections
|
WO2015036394A1
(en)
|
2013-09-10 |
2015-03-19 |
Medimmune Limited |
Antibodies against pd-1 and uses thereof
|
JP6623353B2
(en)
*
|
2013-09-13 |
2019-12-25 |
ベイジーン スウィッツァーランド ゲーエムベーハー |
Anti-PD-1 antibodies and their use for therapy and diagnosis
|
EP3049442A4
(en)
|
2013-09-26 |
2017-06-28 |
Costim Pharmaceuticals Inc. |
Methods for treating hematologic cancers
|
US20150273033A1
(en)
|
2013-11-05 |
2015-10-01 |
Cognate Bioservices, Inc. |
Combinations of checkpoint inhibitors and therapeutics to treat cancer
|
US9580504B1
(en)
|
2013-11-07 |
2017-02-28 |
Curetech Ltd. |
Pidilizumab monoclonal antibody therapy following stem cell transplantation
|
KR102362803B1
(en)
|
2013-11-25 |
2022-02-14 |
페임웨이브 리미티드 |
Compositions comprising anti-ceacam1 and anti-pd antibodies for cancer therapy
|
RS59480B1
(en)
|
2013-12-12 |
2019-12-31 |
Shanghai hengrui pharmaceutical co ltd |
Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
|
US9067998B1
(en)
|
2014-07-15 |
2015-06-30 |
Kymab Limited |
Targeting PD-1 variants for treatment of cancer
|
CA2934028A1
(en)
|
2013-12-17 |
2015-06-25 |
Genentech, Inc. |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
CN113402609B
(en)
|
2013-12-20 |
2023-12-05 |
英特维特国际股份有限公司 |
Canine antibodies with modified CH2-CH3 sequences
|
US11708411B2
(en)
|
2013-12-20 |
2023-07-25 |
Wake Forest University Health Sciences |
Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
|
WO2015095811A2
(en)
|
2013-12-20 |
2015-06-25 |
The Board Institute Inc. |
Combination therapy with neoantigen vaccine
|
US10835595B2
(en)
|
2014-01-06 |
2020-11-17 |
The Trustees Of The University Of Pennsylvania |
PD1 and PDL1 antibodies and vaccine combinations and use of same for immunotherapy
|
TWI681969B
(en)
*
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
Human antibodies to pd-1
|
JOP20200094A1
(en)
*
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
Antibody molecules to pd-1 and uses thereof
|
JOP20200096A1
(en)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
Antibody molecules to tim-3 and uses thereof
|
US20170088626A1
(en)
|
2014-03-05 |
2017-03-30 |
Bristol-Myers Squibb Company |
Treatment of renal cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
|
US9394365B1
(en)
|
2014-03-12 |
2016-07-19 |
Yeda Research And Development Co., Ltd |
Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
|
US11624093B2
(en)
|
2014-04-24 |
2023-04-11 |
Dana-Farber Cancer Institute, Inc. |
Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response
|
BR112016026559A8
(en)
|
2014-05-15 |
2021-07-13 |
Bristol Myers Squibb Co |
use of an anti-pd-1 antibody and another anticancer agent in combination with dual platinum-based (pt-dc) chemotherapy and kit
|
US20160031990A1
(en)
|
2014-05-29 |
2016-02-04 |
Medlmmune, Llc |
Antagonists of pdl-1 and pd-1 for the treatment of hpv-negative cancers
|
US10092645B2
(en)
|
2014-06-17 |
2018-10-09 |
Medimmune Limited |
Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy
|
JP6526189B2
(en)
|
2014-07-03 |
2019-06-05 |
ベイジーン リミテッド |
Anti-PD-L1 antibodies and their use for therapy and diagnosis
|
CA2958643A1
(en)
|
2014-07-07 |
2016-01-14 |
Dana Farber Cancer Institute, Inc. |
Methods of treating cancer
|
BR112017001385B1
(en)
|
2014-07-22 |
2023-12-05 |
Cb Therapeutics, Inc. |
ISOLATED ANTIBODY OR FRAGMENT THEREOF THAT BINDS PD-1, USE OF IT, COMPOSITION, ISOLATED POLYNUCLEOTIDE AND EXPRESSION VECTOR
|
CN105330740B
(en)
|
2014-07-30 |
2018-08-17 |
珠海市丽珠单抗生物技术有限公司 |
Anti- PD-1 antibody and its application
|
EP3936145A1
(en)
|
2014-07-31 |
2022-01-12 |
The University Of Western Australia |
A method for the identification of immunotherapy-drug combinations using a network approach
|
CN105296433B
(en)
|
2014-08-01 |
2018-02-09 |
中山康方生物医药有限公司 |
A kind of CTLA4 antibody, its medical composition and its use
|
US9982052B2
(en)
|
2014-08-05 |
2018-05-29 |
MabQuest, SA |
Immunological reagents
|
ES2921875T3
(en)
|
2014-08-11 |
2022-09-01 |
Acerta Pharma Bv |
Therapeutic combinations of a BTK inhibitor, a PD-1 inhibitor and/or a PD-L1 inhibitor
|
IL250583B
(en)
|
2014-08-19 |
2022-07-01 |
Merck Sharp & Dohme |
Anti-tigit antibodies
|
US20170247455A1
(en)
|
2014-08-22 |
2017-08-31 |
Bristol-Myers Squibb Company |
Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody
|
KR20170066546A
(en)
|
2014-10-03 |
2017-06-14 |
노파르티스 아게 |
Combination therapies
|
CU20170052A7
(en)
|
2014-10-14 |
2017-11-07 |
Dana Farber Cancer Inst Inc |
ANTIBODY MOLECULES THAT JOIN PD-L1
|
GB201419084D0
(en)
|
2014-10-27 |
2014-12-10 |
Agency Science Tech & Res |
Anti-PD-1 antibodies
|
WO2016077397A2
(en)
|
2014-11-11 |
2016-05-19 |
Sutro Biopharma, Inc. |
Anti-pd-1 antibodies, compositions comprising anti-pd-1 antibodies and methods of using anti-pd-1 antibodies
|
KR20210069124A
(en)
|
2014-11-13 |
2021-06-10 |
더 존스 홉킨스 유니버시티 |
Checkpoint blockade and microsatellite instability
|
TWI595006B
(en)
|
2014-12-09 |
2017-08-11 |
禮納特神經系統科學公司 |
Anti-pd-1 antibodies and methods of use thereof
|
WO2016100561A2
(en)
|
2014-12-16 |
2016-06-23 |
Bristol-Myers Squibb Company |
Use of immune checkpoint inhibitors in central nervous systems neoplasms
|
US10239942B2
(en)
|
2014-12-22 |
2019-03-26 |
Pd-1 Acquisition Group, Llc |
Anti-PD-1 antibodies
|
TWI708786B
(en)
|
2014-12-23 |
2020-11-01 |
美商必治妥美雅史谷比公司 |
Antibodies to tigit
|
JP2018506280A
(en)
|
2015-02-06 |
2018-03-08 |
カドモン コーポレイション,リミティド ライアビリティ カンパニー |
Immunomodulator
|
WO2016137985A1
(en)
|
2015-02-26 |
2016-09-01 |
Merck Patent Gmbh |
Pd-1 / pd-l1 inhibitors for the treatment of cancer
|
AR103726A1
(en)
|
2015-02-27 |
2017-05-31 |
Merck Sharp & Dohme |
HUMAN ANTI-PD-1 MONOCLONAL ANTIBODY CRYSTALS
|
WO2016149387A1
(en)
|
2015-03-18 |
2016-09-22 |
The Johns Hopkins University |
Androgen deprivation with immune checkpoint blockade delays the development of castration resistant prostate cancer
|
US20180088111A1
(en)
|
2015-04-14 |
2018-03-29 |
Bristol-Myers Squibb Company |
IMMUNOASSAY FOR SOLUBLE PROGRAMMED DEATH-1 (sPD-1) PROTEIN
|
WO2016172624A1
(en)
|
2015-04-22 |
2016-10-27 |
Agenus Inc. |
Methods for treating cancer
|
WO2016176503A1
(en)
|
2015-04-28 |
2016-11-03 |
Bristol-Myers Squibb Company |
Treatment of pd-l1-negative melanoma using an anti-pd-1 antibody and an anti-ctla-4 antibody
|
WO2016176504A1
(en)
|
2015-04-28 |
2016-11-03 |
Bristol-Myers Squibb Company |
Treatment of pd-l1-positive melanoma using an anti-pd-1 antibody
|
SG11201708804WA
(en)
|
2015-05-07 |
2017-11-29 |
Agenus Inc |
Anti-ox40 antibodies and methods of use thereof
|
US20180256715A1
(en)
|
2015-05-13 |
2018-09-13 |
The Board Of Regents Of The University Of Texas System |
Anti-ctla-4 blockade
|
US20160347836A1
(en)
|
2015-05-28 |
2016-12-01 |
Bristol-Myers Squibb Company |
Treatment of hodgkin's lymphoma using an anti-pd-1 antibody
|
SG10201913500TA
(en)
|
2015-05-29 |
2020-03-30 |
Agenus Inc |
Anti-ctla-4 antibodies and methods of use thereof
|
US11078278B2
(en)
|
2015-05-29 |
2021-08-03 |
Bristol-Myers Squibb Company |
Treatment of renal cell carcinoma
|
CN105061597B
(en)
|
2015-06-09 |
2016-04-27 |
北京东方百泰生物科技有限公司 |
The monoclonal antibody of a kind of anti-PD-1 and preparation method thereof
|
MX2017016353A
(en)
|
2015-06-17 |
2018-05-02 |
Genentech Inc |
Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes.
|
TWI773647B
(en)
|
2015-06-23 |
2022-08-11 |
史隆凱特林紀念癌症中心 |
Novel pd-1 immune modulating agents
|
KR20180040138A
(en)
|
2015-07-13 |
2018-04-19 |
싸이톰스 테라퓨틱스, 인크. |
Anti-PD-1 antibodies, activatable anti-PD-1 antibodies, and methods of using them
|
US10544224B2
(en)
|
2015-07-14 |
2020-01-28 |
Bristol-Myers Squibb Company |
Method of treating cancer using immune checkpoint inhibitor
|
CN106699888B
(en)
|
2015-07-28 |
2020-11-06 |
上海昀怡健康科技发展有限公司 |
PD-1 antibody and preparation method and application thereof
|
KR20180034588A
(en)
|
2015-07-30 |
2018-04-04 |
마크로제닉스, 인크. |
PD-1-binding molecules and methods for their use
|
WO2017024465A1
(en)
|
2015-08-10 |
2017-02-16 |
Innovent Biologics (Suzhou) Co., Ltd. |
Pd-1 antibodies
|
WO2017024515A1
(en)
|
2015-08-11 |
2017-02-16 |
Wuxi Biologics (Cayman) Inc. |
Novel anti-pd-1 antibodies
|
EA201890630A1
(en)
|
2015-09-01 |
2018-10-31 |
Эйдженус Инк. |
ANTIBODIES AGAINST PD-1 AND METHODS OF THEIR APPLICATION
|
CR20220186A
(en)
|
2015-09-25 |
2022-07-07 |
Genentech Inc |
Anti-tigit antibodies and methods of use
|
AU2016329960A1
(en)
|
2015-09-28 |
2018-04-26 |
Jiangsu Hengrui Medicine Co., Ltd. |
Stable anti-PD-1 antibody pharmaceutical preparation and application thereof in medicine
|
EP3356416B1
(en)
|
2015-09-29 |
2021-03-24 |
Shanghai Zhangjiang Biotechnology Co., Ltd |
Pd-1 antibodies and uses thereof
|
EA201890790A1
(en)
|
2015-09-29 |
2018-10-31 |
Селджин Корпорейшн |
CONNECTING PD-1 PROTEINS AND METHODS OF THEIR APPLICATION
|
CN108368176B
(en)
|
2015-10-01 |
2022-06-07 |
波滕扎治疗公司 |
anti-TIGIT antigen binding proteins and methods of use thereof
|
AU2016329251B2
(en)
|
2015-10-02 |
2023-02-02 |
F. Hoffmann-La Roche Ag |
Anti-PD1 antibodies and methods of use
|
HUE059788T2
(en)
|
2015-10-02 |
2022-12-28 |
Symphogen As |
Anti-pd-1 antibodies and compositions
|
WO2017079303A1
(en)
|
2015-11-02 |
2017-05-11 |
The Cleveland Clinic Foundation |
Sequentially orchestrated immune checkpoint therapy for the treatment and prevention of cancer
|
WO2017079080A1
(en)
|
2015-11-02 |
2017-05-11 |
The Johns Hopkins University |
Method of preventing organ transplant rejections using agonists to the pd-1 checkpoint pathway
|
WO2017087280A1
(en)
|
2015-11-16 |
2017-05-26 |
Genentech, Inc. |
Methods of treating her2-positive cancer
|
CN106699889A
(en)
|
2015-11-18 |
2017-05-24 |
礼进生物医药科技(上海)有限公司 |
PD-1 resisting antibody and treatment application thereof
|
KR20180085793A
(en)
|
2015-12-02 |
2018-07-27 |
주식회사 에스티큐브 |
Antibodies specific for glycosylated PD-1 and methods for their use
|
GB201522311D0
(en)
|
2015-12-17 |
2016-02-03 |
Photocure Asa |
Use
|
US10392442B2
(en)
|
2015-12-17 |
2019-08-27 |
Bristol-Myers Squibb Company |
Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment
|
CN105669864B
(en)
|
2015-12-23 |
2018-10-16 |
杭州尚健生物技术有限公司 |
Anti-human 1 antibody of programmed death receptor and its preparation method and application
|
WO2017124050A1
(en)
|
2016-01-14 |
2017-07-20 |
Bps Bioscience, Inc. |
Anti-pd-1 antibodies and uses thereof
|
AU2017208819B2
(en)
|
2016-01-22 |
2023-10-19 |
MabQuest SA |
PD1 specific antibodies
|
KR20180101584A
(en)
|
2016-01-27 |
2018-09-12 |
브리스톨-마이어스 스큅 컴퍼니 |
Treatment of lung cancer using a combination of anti-PD-1 antibody and another anticancer agent
|
EP4035681A1
(en)
|
2016-01-28 |
2022-08-03 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods and pharmaceutical composition for the treatment of cancer
|
WO2017129763A1
(en)
|
2016-01-28 |
2017-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of signet ring cell gastric cancer
|
RU2018130831A
(en)
|
2016-01-28 |
2020-03-02 |
Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн |
APPLICATION OF HISTONIC DEACETHYLASE INHIBITORS TO IMPROVE IMMUNOTHERAPY
|
WO2017132827A1
(en)
|
2016-02-02 |
2017-08-10 |
Innovent Biologics (Suzhou) Co., Ltd. |
Pd-1 antibodies
|
US20190048094A1
(en)
|
2016-02-24 |
2019-02-14 |
Oncomed Pharmaceuticals, Inc. |
Redirecting immune responses
|
CN109196121B
(en)
|
2016-02-29 |
2022-01-04 |
基因泰克公司 |
Methods for treatment and diagnosis of cancer
|
CN109476731A
(en)
|
2016-02-29 |
2019-03-15 |
基础医药有限公司 |
The method for the treatment of cancer
|
WO2017160975A1
(en)
|
2016-03-16 |
2017-09-21 |
Bristol-Myers Squibb Company |
Methods of diagnosing and treating lupus
|
CA3046082A1
(en)
*
|
2016-12-07 |
2018-06-14 |
Agenus Inc. |
Antibodies and methods of use thereof
|